Results 101 to 110 of about 42,251 (222)

Integrating Gene Expression With Recurrent Mutations Improves Age‐Stratified Risk Prediction in Acute Myeloid Leukemia

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Background Older adults with acute myeloid leukemia (AML) have inferior outcomes, yet current genetic risk models do not explicitly account for how age modifies the prognostic impact of molecular features. We hypothesized that integrating apoptosis and p53‐related gene expression with recurrent mutations would improve prediction of complete ...
Mobina Shrestha, Salina Dahal, Asis Shrestha, Patricia McNally, Amir Babu Shrestha, Niklas Mackler   +5 more
wiley   +1 more source

Toxic Encephalopathy Developing After High-dose Cytarabine in a Child with Burkitt Lymphoma: A Successful Treatment Case

Journal of Pediatric Emergency and Intensive Care Medicine
Chemotherapy drugs used in the treatment of leukemia and lymphoma can occasionally cause side effects. We present here a rare case of neurotoxicity that occurred after high-dose cytarabine (HiDAC) administration.
Meliha Kübra Kütükçü Görgülü, Can Acıpayam, Tuğba Kandemir Gülmez, Serkan Kırık, Nursel Yurttutan   +4 more
doaj   +1 more source

A Clinically Relevant Drug Interaction Between Busulfan and Rifampin in the Setting of Hematopoietic Stem Cell Transplant Conditioning

Pharmacology Research &Perspectives, Volume 14, Issue 2, April 2026.
ABSTRACT Busulfan is an alkylating agent used in combination with other chemotherapeutic agents and has become a common component of conditioning regimens prior to hematopoietic stem cell transplantation. Busulfan has a very narrow therapeutic index corresponding to the area under the plasma concentration–time curve, with supra‐therapeutic busulfan ...
Colleen Drangines, Janet Laquet, Ranju Kunwor   +2 more
wiley   +1 more source

Phenotype, Management, and Outcomes in Paediatric Acute Pancreatitis: A Real‐Life Cross‐Sectional Study

Acta Paediatrica, Volume 115, Issue 4, Page 951-958, April 2026.
ABSTRACT Aim Limited Canadian data on paediatric acute pancreatitis exist. A meta‐analysis of 48 studies reported equal prevalence of acute pancreatitis among various aetiologies, with rates of severe acute pancreatitis at 13.7% in North America.
Catherine Korman, Doha Elhaoua, Sarah Blain, Thomas Li, Mariam Mohamed, Alessandro David, Colette Deslandres, Ugur Halac, Martha Dirks, Kelly Grzywacz, Michel Lallier, Fernando Alvarez, Prévost Jantchou   +12 more
wiley   +1 more source

Improvements in Real‐World Survival in the Setting of a Recent Paradigm Shift in Acute Myeloid Leukemia Treatment

European Journal of Haematology, Volume 116, Issue 4, Page 416-424, April 2026.
ABSTRACT Therapeutic options for newly diagnosed (ND) acute myeloid leukemia (AML) have increased in recent years, leading to a shift in the treatment paradigm from conventional, intensive chemotherapy toward targeted and less intensive therapy. Since 2017, there has been a surge in FDA approvals for novel therapies, including small molecule inhibitors
Thuy N. Ho, Patrick Willard, Graeme F. Murray, Li Liu, Nolan Wages, Hyun Lee, Keri R. Maher   +6 more
wiley   +1 more source

Hyperleukocytosis and Access to Minimal Residual Disease Testing Impact Outcomes in Children With Newly Diagnosed Acute Myeloid Leukemia in Thailand

Pediatric Blood &Cancer, Volume 73, Issue 3, March 2026.
ABSTRACT Background The survival outcomes among children with acute myeloid leukemia (AML) in low‐ and middle‐income countries are still poor despite adopting modern treatment regimens from developed countries. The study aimed to identify additional potential determinant factors for relapse and death among children with AML in Thailand. Methods In all,
Piya Rujkijyanont, Supak Ukritchon, Angkana Winaichatsak, Pitchayanan Kuwatjanakul, Thirachit Chotsampancharoen, Piti Techavichit, Su‐on Chainansamit, Lalita Sathitsamitphong, Kittima Kanchanakamhaeng, Usanarat Anurathapan, Napat Laoaroon, Chonthida Wangkittikal, Chalinee Monsereenusorn, Watinee Sanpote, Nattaporntira Phalakornkul, Pariwan Sripattanatadasakul, Daranee Isaranimitkul, Pokpong Na Songkhla, Phakatip Sinlapamongkolkul, Jassada Buaboonnam, Samart Pakakasama   +20 more
wiley   +1 more source

Exploring the Vasculitis‐Tumors Link: Epidemiological Patterns, Mechanistic Insights, and Clinical Implications

Advanced Science, Volume 13, Issue 14, 9 March 2026.
This review outlines association between vasculitis and malignancies and provides practical value for clinicians in distinguishing primary vasculitis from malignancy‐associated forms and optimizing patient surveillance, improving recognition of tumor‐associated vasculitis to reduce the risk of misdiagnosis, supporting more accurate clinical decision ...
Xiaofei Shi, Zhijiao Li, Xin Ma, Bei Zhang, Xinfeng Wu, Hua Fan, Rongzeng Liu, Hongwei Jiang, Cong‐Qiu Chu   +8 more
wiley   +1 more source

Extramedullary Disease—Achilles Heel in Myeloma?

American Journal of Hematology, Volume 101, Issue 3, Page 521-536, March 2026.
ABSTRACT Despite advances in therapy, extramedullary disease (EMD) remains an aggressive form of multiple myeloma associated with poor outcomes. Patients with true EMD, in which plasmacytomas have become completely independent of bone, have a particularly poor prognosis. The pathogenesis of EMD is driven by complex mechanisms involving loss of adhesion
Shaji Kumar, Joshua Richter, Saad Z. Usmani, Yael C. Cohen, Jing Christine Ye, María‐Victoria Mateos, Vania Hungria, Elena Zamagni   +7 more
wiley   +1 more source

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy

American Journal of Hematology, Volume 101, Issue 3, Page 512-520, March 2026.
Early cardiac biomarker monitoring in AML induction therapy showed significantly higher hsTnT levels after daunorubicin 90 mg/m2 compared with 60 mg/m2, indicating a dose‐dependent early myocardial effect. ABSTRACT Anthracyclines are an essential component of induction therapy for acute myeloid leukemia (AML), but their optimal dosing and the ...
Stefan Markus Dendorfer, Katharina Schmidt‐Brücken, Michael Kramer, Björn Steffen, Christoph Schliemann, Jan‐Henrik Mikesch, Nael Alakel, Regina Herbst, Mathias Hänel, Maher Hanoun, Martin Kaufmann, Barbora Weinbergerova, Kerstin Schäfer‐Eckart, Tim Sauer, Andreas Neubauer, Andreas Burchert, Claudia D. Baldus, Jolana Mertová, Edgar Jost, Dirk Niemann, Jan Novák, Stefan W. Krause, Sebastian Scholl, Andreas Hochhaus, Gerhard Held, Tomáš Szotkowski, Andreas Rank, Christoph Schmid, Lars Fransecky, Sabine Kayser, Markus Schaich, Frank Fiebig, Annett Haake, Johannes Schetelig, Jan Moritz Middeke, Friedrich Stölzel, Uwe Platzbecker, Christian Thiede, Carsten Müller‐Tidow, Wolfgang E. Berdel, Gerhard Ehninger, Jiri Mayer, Hubert Serve, Martin Bornhäuser, Christoph Röllig   +44 more
wiley   +1 more source

Retrospective Cohort Analysis of Treatment Patterns, Survival, and Cost‐Effectiveness in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in Lower Austria (2018–2022)

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Background R/R DLBCL is an aggressive malignancy with limited treatment options. Novel immunotherapies have improved outcomes in selected clinical‐trial populations, but their effectiveness in real‐world settings remains unclear. Their substantial costs also pose challenges for healthcare systems.
Josef Singer, Sandra Gottsauner‐Wolf, Doris A. Behrens   +2 more
wiley   +1 more source